Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies
Maximilian Merz(Memorial Sloan Kettering Cancer Center), Uwe Platzbecker(National Center for Tumor Diseases), Jan Sonntag(Leipzig University), Enrica Bach, Klaus H. Metzeler(University Hospital Leipzig), Marco Herling(Unknown), Christina Kloetzer(University Hospital Leipzig), Vladan Vučinić(University Hospital Leipzig), Song Yau Wang(University Hospital Leipzig), Saskia Hell, Madlen Jentzsch, Simone Heyn(University Hospital Leipzig), Jule Ussmann(Leipzig University), Birthe Schetschorke(Leipzig University), Sandra Hoffmann(Economic Research Service), Georg‐Nikolaus Franke(University Hospital Leipzig), Sebastian Schwind
Cited by 1
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Annual Cost of Illness and Quality-Adjusted Life Year Losses in the United States Due to 14 Foodborne Pathogens
|Journal of Food Protection|2012|609